MENU
+Compare
MRUS
Stock ticker: NASDAQ
AS OF
Sep 16, 04:59 PM (EDT)
Price
$66.88
Change
-$1.21 (-1.78%)
Capitalization
5.06B

MRUS Merus NV Forecast, Technical & Fundamental Analysis

Merus NV is a clinical-stage immuno-oncology company... Show more

Industry: #Biotechnology
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MRUS with price predictions
Sep 15, 2025

MRUS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for MRUS turned positive on September 11, 2025. Looking at past instances where MRUS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 09, 2025. You may want to consider a long position or call options on MRUS as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRUS advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 242 cases where MRUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MRUS broke above its upper Bollinger Band on September 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.010) is normal, around the industry mean (20.594). P/E Ratio (0.000) is within average values for comparable stocks, (53.282). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.156). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (82.645) is also within normal values, averaging (342.112).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

MRUS is expected to report earnings to fall 38.12% to -137 cents per share on October 30

Merus NV MRUS Stock Earnings Reports
Q3'25
Est.
$-1.38
Q2'25
Missed
by $1.07
Q1'25
Missed
by $0.29
Q4'24
Beat
by $0.48
Q3'24
Missed
by $0.60
The last earnings report on August 05 showed earnings per share of -223 cents, missing the estimate of -115 cents. With 634.70K shares outstanding, the current market capitalization sits at 5.06B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Uppsalalaan 17
Phone
+31 302538800
Employees
229
Web
https://www.merus.nl
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BEXIX19.260.17
+0.87%
Baron Emerging Markets Institutional
VBIAX52.29N/A
N/A
Vanguard Balanced Index Adm
MIVIX28.97N/A
N/A
Madison Large Cap I
SJVIX30.84N/A
N/A
Steward Large Cap Value I
CSHZX12.19-0.05
-0.41%
NYLI Cushing® MLP Premier Class I

MRUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with CGON. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
-2.14%
CGON - MRUS
51%
Loosely correlated
+3.78%
RVMD - MRUS
49%
Loosely correlated
-0.75%
IDYA - MRUS
49%
Loosely correlated
-0.33%
ACLX - MRUS
48%
Loosely correlated
-1.30%
CRNX - MRUS
47%
Loosely correlated
-0.68%
More